Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT05747924 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

FSHD
FSHD1
FSHD2
FMD
FMD2
Fascioscapulohumeral Muscular Dystrophy
Fascioscapulohumeral Muscular Dystrophy Type 1
Fascioscapulohumeral Muscular Dystrophy Type 2
Dystrophies, Facioscapulohumeral Muscular
Dystrophy, Facioscapulohumeral Muscular
Facioscapulohumeral Muscular Dystrophy 1
Facioscapulohumeral Muscular Dystrophy 2
Facio-Scapulo-Humeral Dystrophy
Atrophy, Facioscapulohumeral
Atrophies, Facioscapulohumeral
Facioscapulohumeral Atrophy
Muscular Dystrophies
Muscular Dystrophy, Facioscapulohumeral
FSH Muscular Dystrophy
Landouzy Dejerine Dystrophy
Landouzy-Dejerine Muscular Dystrophy
Dystrophies, Landouzy-Dejerine
Dystrophy, Landouzy-Dejerine
Landouzy-Dejerine Syndrome
Muscular Dystrophy, Landouzy Dejerine
Progressive Muscular Dystrophy
FSH

Interventions

DRUG: AOC 1020
DRUG: Placebo

Sponsor

Avidity Biosciences, Inc.